LEASE by and between BMR-500 FAIRVIEW AVENUE LLC, a Delaware limited liability company and SILVERBACK THERAPEUTICS, INC., a Delaware corporation 500 Fairview Avenue North, Seattle, WashingtonLease • November 10th, 2020 • Silverback Therapeutics, Inc. • Pharmaceutical preparations
THIS LEASE (this “Lease”) “is entered into as of this 8th day of June, 2016 (the “Execution Date”), by and between BMR-500 FAIRVIEW AVENUE LLC, a Delaware limited liability company (“Landlord”), and SILVERBACK THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
INDEMNITY AGREEMENTIndemnification Agreement • November 10th, 2020 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of ___________ _____, 20__, is made by and between SILVERBACK THERAPEUTICS, INC., a Delaware corporation (the “Company”), and _________________ (“Indemnitee”).
CELL LINE LICENSE AGREEMENTCell Line License Agreement • November 10th, 2020 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • New York
This Cell Line License Agreement (“Agreement”), effective as of 11 October 2019 (“EFFECTIVE DATE”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Silverback Therapeutics, Inc., having its principal place of business at 500Fairview Ave. N #600, Seattle, WA 98109 (“Licensee”). WuXi Biologics and Licensee may bereferred to herein individually as a “Party” and collectively as the “Parties.”
ContractWarrant Agreement • November 10th, 2020 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
MASTER SERVICES AGREEMENTMaster Services Agreement • November 10th, 2020 • Silverback Therapeutics, Inc. • Pharmaceutical preparations
THIS MASTER SERVICES AGREEMENT is made and entered into as of January 21, 2020 (the “Effective Date”) by and between CE3 INC. having a principal place of business at 246 Goose Lane, Suite 202, Guilford, CT, USA (“CE3”) and Silverback Therapeutics, Inc., having a principal place of business at 500 Fairview Ave N, #600, Seattle WA 98109 (“Sponsor”). The term “CE3” includes CE3, Inc., its affiliates, and authorized agents. The term “Sponsor” includes Silverback Therapeutics, Inc. and its authorized agents.
MASTER LABORATORY SERVICES AGREEMENTMaster Laboratory Services Agreement • November 10th, 2020 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • New York
This Master Laboratory Services Agreement (“Agreement”), when signed by the parties, will set forth the terms and conditions between Silverback Therapeutics, Inc., with its principal offices located at 500 Fairview Avenue North, Suite 600, Seattle, WA 98109, United States (“Customer”) and Q Squared Solutions LLC, with its principal offices located at 5827 South Miami Blvd, Morrisville, NC 27560, USA (“Q Squared”), under which Q Squared agrees to provide laboratory services to Customer as set forth below.
